Thelansis Expands Market Access Advisory to Help Biopharma Optimize Pricing, HTA, and Reimbursement for Successful Commercialization

The new consulting service combines payer value assessment, cross-market pricing analytics, HTA evidence planning, and launch strategy to help biopharma companies identify access risks before critical commercial decisions are made.

As reimbursement environments become increasingly demanding and pricing decisions more interconnected across global markets, biopharma companies face mounting pressure to demonstrate not only clinical benefit but also economic value. Regulatory approval alone is no longer enough to ensure commercial success. Organizations must navigate evolving payer expectations, health technology assessment (HTA) requirements, and complex pricing regulations that vary significantly across healthcare systems.

Recognizing these challenges, Thelansis Knowledge Partners LLP, a life sciences market intelligence and consulting firm, has strengthened its consulting portfolio with a dedicated Market Access Advisory practice. The service is designed to help pharmaceutical and biotechnology companies develop evidence-driven pricing, reimbursement, and market access strategies that improve launch readiness while maximizing long-term commercial potential.

Learn more about Thelansis Market Access Consulting: https://thelansis.com/market-access/

Why This Matters Now
Clinical success and commercial access have become increasingly separate challenges. A therapy can demonstrate strong efficacy in Phase III and achieve regulatory approval, yet still encounter delayed reimbursement, restricted patient access, or significant pricing pressure if payer expectations are not addressed early.

Across major global markets, HTA agencies and reimbursement authorities are placing greater emphasis on comparative clinical value, real-world evidence, health economics, budget impact, and long-term outcomes. By the time a disconnect between pricing strategy and payer expectations becomes apparent, launch sequencing, evidence generation, and commercialization plans are often already fixed.

Thelansis' Market Access Advisory is built to identify these risks early, when pricing assumptions, evidence strategies, and launch plans can still be optimized.

What the Service Covers
The Market Access Advisory practice provides strategic support across the commercialization journey, including:
• Early Payer Value Assessment (EPVA)
• Pricing and reimbursement landscape analysis
• Market access opportunity and barrier assessment
• Value proposition and value story development
• Health Technology Assessment (HTA) evidence planning
• Health economics and reimbursement strategy support
• Evidence gap assessment and real-world evidence planning
• Launch sequencing based on market access probability
• Cross-market pricing strategy and external reference pricing analysis
• Commercial access risk assessment and scenario modelling

What Sets Thelansis Apart
While many market access engagements focus primarily on reimbursement submissions, Thelansis approaches market access as a strategic commercial planning function that begins well before launch.
The practice is distinguished by:
• Early access risk identification through payer value assessment before pricing and evidence strategies are finalized.
• Cross-market pricing intelligence that models external reference pricing (ERP), price corridor scenarios, confidential discount assumptions, and reimbursement interdependencies across global markets.
• Integrated evidence planning that connects clinical development, HEOR, real-world evidence, and HTA expectations into a practical roadmap for market access readiness.
Scenario-based commercial decision support, allowing teams to evaluate different pricing, sequencing, and reimbursement strategies before making irreversible launch decisions.
• Transparent, evidence-driven modelling, where every recommendation is supported by clearly documented assumptions, published evidence, payer precedents, and market-specific intelligence rather than black-box forecasting.

Proof in Practice: Protecting Global Price Integrity Across 15 Markets
One recent engagement involved a biopharma company preparing the global launch of a first-in-class immunology therapy across fifteen strategically important markets. The challenge extended beyond determining an initial list price, it required protecting long-term global price integrity in markets connected through complex external reference pricing (ERP) systems.

Thelansis mapped payer elasticity across all fifteen markets using historical HTA decisions, reimbursement thresholds, local pricing precedents, and payer willingness-to-pay benchmarks. The team developed market-specific price corridors while modelling external reference pricing relationships, anticipated confidential discounts, mandatory rebates, clawback mechanisms, and exchange-rate sensitivities.

The analysis demonstrated that a suboptimal pricing decision in only two markets could reduce projected global revenue potential by nearly 18% within three years through cascading ERP effects.

Based on these findings, the client refined its launch sequencing, strengthened HTA submissions with market-specific value justification, and successfully secured reimbursement approvals across its first-wave launch markets without triggering avoidable price erosion in ERP-sensitive regions.

Read full case study: Building a Global Price Strategy: How Thelansis Helped a Biopharma Set the Right Launch Price Across 15 Markets: https://thelansis.com/case-studies/building-a-global-price-strategy-how-thelansis-helped-a-biopharma-set-the-right-launch-price-across-15-markets/

Questions We Help Clients Answer
Biopharma companies frequently engage Thelansis to answer critical commercialization questions such as:

What price can each market realistically sustain?
Which countries should be prioritized to protect global pricing?
Where are the most significant HTA evidence gaps?
Which clinical outcomes are most likely to resonate with payers?
How will external reference pricing influence long-term revenue?
Which reimbursement barriers are likely to delay patient access?
How should value be communicated across different healthcare systems?

Who This Is For
The Market Access Advisory practice is designed for pharmaceutical, biotechnology, specialty pharma, and emerging biotech companies preparing for commercialization, evaluating pricing strategy, developing HTA evidence packages, planning multi-market launches, or expanding into new international markets.

Engagements can range from targeted payer assessments for a single indication to comprehensive global market access strategies supporting complex, multi-country product launches.

Looking Ahead
As healthcare systems place greater emphasis on value-based reimbursement and evidence-driven decision-making, market access planning is becoming a strategic capability rather than a late-stage commercialization activity. Organizations that align pricing strategy, evidence generation, and payer expectations early are better positioned to achieve timely reimbursement, protect global pricing, and accelerate patient access.

Through its expanded Market Access Advisory practice, Thelansis helps biopharma companies move beyond regulatory approval toward sustainable commercial success by integrating pricing, reimbursement, and evidence planning into a cohesive market access strategy from the outset.

To learn more about Thelansis Market Access Advisory or explore how the team supports global pricing and reimbursement strategy, visit: https://thelansis.com/market-access/

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.